Siliq Disease Interactions

The use of brodalumab is contraindicated in patients with Crohn's disease as this agent may cause worsening of the disease. It is recommended to discontinue the use of brodalumab if patients develop Crohn's disease while on treatment.

Suicidal ideation and behavior, including completed suicides, have occurred in patients treated with brodalumab. Patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior. Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior. Prescribers should weigh the potential risks and benefits before using brodalumab in patients with a history of depression or suicidality. Families and caregivers should be advised of the need for close observation and communication with the treating physician.

Brodalumab should not be administered to patients with active tuberculosis infection. It is recommended to evaluate patients for tuberculosis infection prior to initiating treatment with brodalumab and initiate treatment for latent tuberculosis prior to administering this agent. Consider anti- tuberculosis therapy prior to initiation of therapy in patients with a past history of latent or active tuberculosis in whom an adequate course of treatment cannot be confirmed. Closely monitor patients receiving brodalumab for signs and symptoms of active tuberculosis during and after treatment.

The use of live vaccines in patients treated with brodalumab should be avoided. No data are available on the ability of live or inactive vaccines to elicit an immune response in patients being treated with this agent.

The use of brodalumab of may increase the risk of infections. When using this agent in patients with a chronic infection or a history of recurrent infection, it is recommended to consider the risks and benefits prior to prescribing brodalumab. Therapy discontinuation may be considered if a patient develops a serious infection or is not responding to standard therapy for the infection. Care should be exercised when prescribing this agent to patients with an existing infection.